It is a national, retrospective , observational study in hypertensive patients treated for at least 8 weeks with the fixed dose combination of telmisartan 80 mg and hydrochlorothiazide 25 mg. The primary objective is to assess the control rate (systolic and diastolic blood pressure). Key secondary objectives are to assess the blood pressure reduction after at least 8 weeks of treatment, describe the population treated with this new fixed dose combination
Study Type
OBSERVATIONAL
Enrollment
2,411
Rate of BP Control in Hypertensive Patients
Percentage of controlled Patients at the Study End. Control rate of hypertension in general practice and in cardiology defined as systolic blood pressure (SBP) and diastolic blood pressure (DBP) \<140/90 mmHg for unselected hypertensive patients and SBP and DBP \<130/80 mmHg for hypertensive patients at high cardiovascular risk (patients with diabetes and patients with impaired renal function) as defined in the recommendations of the French National Health Authority (HAS) 2005 guidelines.
Time frame: Baseline to a minimum of 8 weeks of treatment
Systolic Blood Pressure (SBP) After at Least 8 Weeks of Treatment in Overall Study Population
Mean SBP measured at the Study End
Time frame: baseline to a minimum of 8 weeks of treatment
Diastolic Blood Pressure (DBP) After at Least 8 Weeks of Treatment in Overall Study Population
Mean DBP measured at the Study End
Time frame: baseline to a minimum of 8 weeks of treatment
Systolic Blood Pressure (SBP) After at Least 8 Weeks of Treatment in Population at High Cardiovascular Risk
Mean SBP measured at the Study End
Time frame: baseline to a minimum of 8 weeks of treatment
Diastolic Blood Pressure (DBP) After at Least 8 Weeks of Treatment in Population at High Cardiovascular Risk
Mean DBP measured at the Study End
Time frame: baseline to a minimum of 8 weeks of treatment
Rate of BP Control by Risk Factor According to the Recommendations ESH/ESC 2007
The proportion of patients with blood pressure (BP) control, per risk factor. High risk factors determined according to the recommendations of the ESH/ESC 2007.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Boehringer Ingelheim Investigator site 1
Ablon-sur-Seine, France
Boehringer Ingelheim Investigator site 2
Achenheim, France
Boehringer Ingelheim Investigator site 3
Afa, France
Boehringer Ingelheim Investigator site 4
Aiguillon, France
Boehringer Ingelheim Investigator site 5
Aire-sur-l'Adour, France
Boehringer Ingelheim Investigator site 6
Aix-en-Othe, France
Boehringer Ingelheim Investigator site 7
Aix-en-Provence, France
Boehringer Ingelheim Investigator site 8
Aix-en-Provence, France
Boehringer Ingelheim Investigator site 9
Aix-les-Bains, France
Boehringer Ingelheim Investigator site 10
Ajaccio, France
...and 905 more locations
Time frame: Baseline to a minimum of 8 weeks of treatment